Urinary lithogenic risk profile in ADPKD patients treated with Tolvaptan

被引：0
|
作者：
Bargagli, Matteo [1 ]
Dhayat, Nasser [2 ]
Anderegg, Manuel [2 ]
Semmo, Mariam [2 ]
Huynh-Do, Uyen [2 ]
Vogt, Bruno [2 ]
Ferraro, Pietro Manuel [1 ]
Fuster, Daniel [2 ]
机构：
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, UOC Nefrol, Rome, Italy
[2] Univ Bern, Bern Univ Hosp, Inselspital, Div Nephrol & Hypertens, Bern, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 36
引用
收藏
页码：26S / 26S
页数：1
相关论文
共 50 条
  • [21] IMPLEMENTING A VIRTUAL NEPHROLOGY PANEL FOR TOLVAPTAN USE IN PATIENTS WITH ADPKD
    Lin Duong
    Taneja, Nidhika
    Belani, Sharina
    Irannejad, Pardis
    Jain, Anagha
    Lieberman, Jonathan
    Tuan Nguyen
    Ramaswamy, Deepa
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 77 (04) : 590 - 590
  • [22] ADAPTING THE ADPKD OUTCOMES MODEL TO PREDICT COST CONSEQUENCE IN ITALIAN PATIENTS WITH AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) TREATED WITH JINARC (TOLVAPTAN)
    Mennini, F. S.
    Marcellusi, A.
    Russo, S.
    Iorio, A.
    Lanati, E. P.
    Robinson, P.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [23] Retrospective Review of Serum and Urinary Lithogenic Risk Factors in Patients With Osteoporosis and Osteopenia
    Angel Arrabal-Polo, Miguel
    Sierra Giron-Prieto, Maria
    del Carmen Cano-Garcia, Maria
    Poyatos-Andujar, Antonio
    Quesada-Charneco, Miguel
    Abad-Menor, Felix
    Arias-Santiago, Salvador
    Zuluaga-Gomez, Armando
    Arrabal-Martin, Miguel
    UROLOGY, 2015, 85 (04) : 782 - 785
  • [24] Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
    Mizuno, Hiroki
    Sekine, Akinari
    Suwabe, Tatsuya
    Ikuma, Daisuke
    Yamanouchi, Masayuki
    Hasegawa, Eiko
    Sawa, Naoki
    Ubara, Yoshifumi
    Hoshino, Junichi
    PLOS ONE, 2022, 17 (02):
  • [25] TREATMENT WITH TOLVAPTAN IN ADPKD PATIENTS: RESULTS FROM AN OBSERVATIONAL, MULTICENTRIC STUDY
    Galliani, Marco
    Vitaliano, Elio
    Chicca, Silvana
    Paone, Antonio
    Pistolesi, Valentina
    Morabito, Santo
    Di Lullo, Luca
    Floccari, Fulvio
    Marrocco, Fulvio
    Cioffi, Massimiliano
    Rifici, Nunzio
    Iacono, Rossella
    Feriozzi, Sandro
    Pasquarelli, Cynthia
    Morosetti, Massimo
    Bernabei, Eleonora
    Ferrazzano, Maria Teresa
    Orossi, Antonella
    Fini, Riziero
    Lai, Silvia
    Mazzaferro, Sandro
    Fulignati, Pierluigi
    Grandaliano, Giuseppe
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [26] Effect of Tolvaptan Treatment on Acid-Base Homeostasis in ADPKD Patients
    Bargagli, Matteo
    Ferraro, Pietro Manuel
    Dhayat, Nasser
    Anderegg, Manuel
    Fuster, Daniel
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (06): : 1749 - 1749
  • [27] Urinary fingerprints unique to patients with ADPKD
    Helene Myrvang
    Nature Reviews Nephrology, 2011, 7 (5) : 244 - 244
  • [28] EFFICACY AND SAFETY OF TOLVAPTAN ON ADPKD PATIENTS IN LATE-STAGE CKD
    Hattanda, Fumihiko
    Makita, Minoru
    Kawashima, Keisuke
    Kondo, Keiichi
    Kusunoki, Yoshihiro
    Matsuoka, Naoko
    Yamamoto, Junya
    Nakagaki, Tasuku
    Nishio, Saori
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 92 - 92
  • [29] TWO YEARS EXPERIENCE OF TOLVAPTAN TREATMENT FOR TWENTY-THREE ADPKD PATIENTS
    Nomura, Shinsuke
    Endo, Mayumi
    Matsuo, Hiroshi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 97 - 97
  • [30] Transcriptomic and metabolic profiling of Tolvaptan treated Autosomal dominant polycystic kidney disease (ADPKD) patient
    Lin, Hugo Y.
    Xu, Frank
    Ho, Li-Lun
    Huang, Li-Ju
    Lu, Tzongshi
    FASEB JOURNAL, 2022, 36
12345